Sanofi: Dupixent Meets Primary Endpoints In ADEPT pivotal study in BP
I'm PortAI, I can summarize articles.
Sept 11 (Reuters) - Sanofi SA (SASY.PA) :DUPIXENT IS THE FIRST AND ONLY BIOLOGIC TO ACHIEVE SIGNIFICANT IMPROVEMENTS IN DISEASE REMISSION AND SYMPTOMS IN BULLOUS PEMPHIGOID POSITIVE PIVOTAL STUDYSTUDY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN ADULTS WITH MODERATE-TO-SEVERE DISEASEFIVE TIMES MORE PATIENTS ACHIEVED SUSTAINED DISEASE REMISSION WITH DUPIXENT THAN PLACEBOSTUDY WILL SUPPORT REGULATORY SUBMISSIONS AROUND WORLD, STARTING WITH U.S. LATER THIS YEARSAFETY AND EFFICACY OF DUPIXENT IN BP AND CPUO ARE CURRENTLY UNDER CLINICAL INVESTIGATION AND HAVE NOT BEEN EVALUATED BY ANY REGULATORY AUTHORITY
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments